Savara Inc. (SVRA)
| Bid | 2.26 |
| Market Cap | 397.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -67.19M |
| EPS (ttm) | -0.43 |
| PE Ratio (ttm) | -5.38 |
| Forward PE | -5.92 |
| Analyst | Buy |
| Ask | 2.5 |
| Volume | 977,314 |
| Avg. Volume (20D) | 991,806 |
| Open | 2.48 |
| Previous Close | 2.49 |
| Day's Range | 2.31 - 2.50 |
| 52-Week Range | 2.31 - 5.70 |
| Beta | 0.63 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas....
Analyst Forecast
According to 7 analyst ratings, the average rating for SVRA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 288.77% from the latest price.
2 months ago · businesswire.com
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceLANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will presen...